Loading...
•
Dec 31, 2025
AbbVie Q4 2025 Earnings Report
AbbVie reported solid fourth-quarter results with double-digit revenue growth and improved operating performance.
Key Takeaways
AbbVie delivered strong Q4 2025 results with revenue growth driven by its immunology and neuroscience portfolios, solid profitability, and improved margins despite higher acquired IPR&D and milestones expense.
Q4 revenue increased to $16.62 billion driven by strong immunology growth.
Adjusted EPS showed solid performance despite acquisition-related expenses.
Operating margins improved on both GAAP and adjusted bases.
Continued portfolio diversification reduced reliance on legacy products.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
AbbVie issued positive full-year 2026 adjusted EPS guidance, reflecting confidence in continued growth.
Positive Outlook
- Strong outlook for immunology portfolio growth.
- Continued expansion of neuroscience products.
- Diversified revenue base reduces single-product risk.
- Robust pipeline supports long-term growth.
- Improving operational efficiency.
Challenges Ahead
- Potential impact from future acquired IPR&D expenses.
- Ongoing decline in legacy product revenues.
- Regulatory and pricing pressures in key markets.
- Foreign exchange volatility risk.
- Macroeconomic uncertainty affecting healthcare spending.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...